Bifidobacterium longum PL03, Lactobacillus rhamnosus KL53A, and Lactobacillus plantarum PL02 in the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Controlled Pilot Trial

Digestion ◽  
2008 ◽  
Vol 78 (1) ◽  
pp. 13-17 ◽  
Author(s):  
Henryk Szymański ◽  
Małgorzata Armańska ◽  
Kinga Kowalska-Duplaga ◽  
Hania Szajewska
Keyword(s):  
Lactobacillus Plantarum ◽  
Bifidobacterium Longum ◽  
Pilot Trial ◽  
Lactobacillus Rhamnosus ◽  
Randomized Controlled ◽  
Antibiotic Associated Diarrhea

The safety and efficacy of denosumab versus zoledronic acid in the treatment of pediatric osteoporosis: a randomized controlled pilot trial

2019 ◽  
Author(s):  
Marie-Eve Robinson ◽  
Jinhui Ma ◽  
Nasrin Khan ◽  
Karine Khatchadourian ◽  
Marika Page ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Pilot Trial ◽  
Safety And Efficacy ◽  
Randomized Controlled

Irritable bowel syndrome and probiotics place in therapeutic strategies

Infectio ro ◽  
2018 ◽  
Vol 56 (4) (1) ◽  
pp. 9-21
Author(s):  
Ștefan-Sorin Aramă
Keyword(s):  
Irritable Bowel Syndrome ◽  
Optimal Strategy ◽  
Vitamin B6 ◽  
Scientific Evidence ◽  
Bifidobacterium Longum ◽  
Lactobacillus Rhamnosus ◽  
Therapeutic Strategies ◽  
Intestinal Dysbiosis ◽  
Irritable Bowel ◽  
The Moment

Irritable bowel syndrome is a frequent digestive condition, with an unclear etiopathogeny. Very probably intestinal dysbiosis plays an important role. For the moment there are no guidelines for treatment. There is scientific evidence for several therapies: modification of diet, non-resorbable antibiotics (rifaximin-α) and probiotics. Giving probiotics after each antibiotic course (an association of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001) supplemented with vitamin B6 may be an optimal strategy.

Sign in / Sign up

Export Citation Format

Share Document